FDA Rejects “Approvable” And “Not Approvable” Letters
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency will begin Aug. 11 to use “complete response” letters instead.
You may also be interested in...
FDA: BioDelivery Sciences Should Improve “Safe Use” REMS Provisions For Oral Fentanyl Approval
Onsolis “complete response” letter is “as close to approval as one can get without having it,” BDSI CEO says.
FDA: BioDelivery Sciences Should Improve “Safe Use” REMS Provisions For Oral Fentanyl Approval
Onsolis “complete response” letter is “as close to approval as one can get without having it,” BDSI CEO says.
FDA To Investors: Ask For The Letter
Top new drug review officials feel biopharma investors' pain when it comes to interpreting "complete response" actions.